Literature DB >> 16082633

Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey.

Hyon K Choi1, John D Seeger.   

Abstract

OBJECTIVE: It has been generally perceived that glucocorticoids adversely affect serum lipid levels, although results of prospective studies have suggested the contrary. In this study, we sought to examine the relationship between glucocorticoid use and lipid profiles in a nationally representative sample of subjects.
METHODS: Using data from 15,004 participants ages 20 years and older in The Third National Health and Nutrition Examination Survey (1988-1994), we examined the relationship between glucocorticoid use and serum lipid profiles. Glucocorticoid use was determined from the household interview regarding prescription medication use. We used multivariate linear regression to adjust for age, sex, race or ethnicity, education, smoking status, body mass index, physical activity, alcohol consumption, energy fraction from protein and carbohydrates, and total energy intake.
RESULTS: Glucocorticoid use was associated with a higher serum high-density lipoprotein (HDL) cholesterol level and a lower ratio of total cholesterol-to-HDL cholesterol among subjects ages 60 years or older (multivariate difference 9.0 mg/dl [95% confidence interval (95% CI) 3.9, 14.1] and -0.6 mg/dl [95% CI -0.9, -0.3], respectively) but not among those younger than age 60 years (multivariate difference -1.5 mg/dl [95% CI -5.4, 2.5] and 0.1 mg/dl [95% CI -0.3, 0.5], respectively). Correspondingly, glucocorticoid use was associated with a higher serum apolipoprotein A-I (Apo A-I) level and a lower Apo A-I:Apo B ratio (multivariate difference 12.1 mg/dl [95% CI 2.9, 21.3] and 0.16 mg/dl [95% CI 0.03, 0.29], respectively) only among subjects ages 60 years or older. Inhalation/intranasal glucocorticoid use was also associated with a higher serum HDL cholesterol level (multivariate difference 4.9 mg/dl [95% CI 0.3, 9.5]) only among subjects ages 60 years or older.
CONCLUSION: Our results suggest that glucocorticoid use is not associated with an adverse lipid profile in the US population and may be associated with a favorable lipid profile among persons ages 60 years or older, in concordance with previous prospective studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082633     DOI: 10.1002/art.21329

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

1.  Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics.

Authors:  Xuewen Wang; Faidon Magkos; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Bettina Mittendorfer
Journal:  Eur J Endocrinol       Date:  2012-05-22       Impact factor: 6.664

Review 2.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

Review 3.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

4.  Differing trends in the incidence of vascular comorbidity in MS and the general population.

Authors:  Amin Zarghami
Journal:  Neurol Clin Pract       Date:  2016-06

Review 5.  Prevention and treatment of systemic glucocorticoid side effects.

Authors:  Siamak Moghadam-Kia; Victoria P Werth
Journal:  Int J Dermatol       Date:  2010-03       Impact factor: 2.736

Review 6.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

Review 7.  Conference summary and conclusions. A comprehensive approach to predicting and managing mood effects of glucocorticoids.

Authors:  Esther M Sternberg; Lewis L Judd
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

8.  Effect of glucocorticoids on serum lipid profile and endothelial function and arterial wall mechanics.

Authors:  Anita Yadav; Afsana Jahan; Tribhuvan Pal Yadav; Namrita Sachdev; Anubhuti Chitkara; Ram Asare
Journal:  Indian J Pediatr       Date:  2013-05-22       Impact factor: 1.967

Review 9.  Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.

Authors:  Laurence Fardet; Bruno Fève
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

10.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.